Celldex Therapeutics Inc. (CLDX)

Schlusskurs vom Vortag:

$36.26

Offen:

$36.31

24-Stunden-Volumen:

322.02K

Marktkapitalisierung:

$2.38B

Einnahmen:

$6.88M

Nettoeinkommen (Verlust:

$-141.43M

KGV:

-13.75

EPS:

-2.64

Netto-Cashflow:

$-109.11M

1W Leistung:

-4.42%

1M Leistung:

-11.55%

6M Leistung:

+55.79%

1J Leistung:

+12.28%

1-Tages-Spanne:

$35.65

$36.74

52-Wochen-Spanne:

$22.11

$53.18

Celldex Therapeutics Inc. Stock (CLDX) Company Profile

Firmenname

Celldex Therapeutics Inc.

Sektor

Healthcare (1191)

Branche

Biotechnology (688)

Telefon

908-200-7500

Adresse

Perryville III Building, Suite 220 53 Frontage Road, Hampton

Mitarbeiter

192

Twitter

@search?q=celldex

Nächster Verdiensttermin

2024-05-02

Neueste SEC-Einreichungen

CLDX's Discussions on Twitter

Celldex Therapeutics Inc. Stock (CLDX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2023-12-20	Eingeleitet	TD Cowen	Outperform
2023-11-10	Hochstufung	Wells Fargo	Underweight → Equal Weight
2023-08-22	Eingeleitet	Wells Fargo	Underweight
2021-09-17	Eingeleitet	Jefferies	Buy
2021-09-10	Eingeleitet	SVB Leerink	Outperform
2021-07-22	Eingeleitet	Guggenheim	Buy
2020-02-21	Eingeleitet	Cantor Fitzgerald	Overweight
2017-08-01	Fortgesetzt	H.C. Wainwright	Buy
2016-11-07	Eingeleitet	Aegis Capital	Buy
2016-03-08	Herabstufung	Jefferies	Buy → Hold
2016-03-07	Herabstufung	Guggenheim	Buy → Neutral
2016-03-07	Herabstufung	Leerink Partners	Outperform → Mkt Perform
2016-03-07	Herabstufung	Wedbush	Outperform → Neutral
2016-03-01	Eingeleitet	H.C. Wainwright	Buy
2015-08-11	Bestätigt	Brean Capital	Buy
2015-08-11	Bestätigt	Oppenheimer	Outperform
2015-08-11	Bestätigt	ROTH Capital	Buy
2015-06-02	Bestätigt	WBB Securities	Strong Buy
2014-11-17	Bestätigt	ROTH Capital	Buy
2014-03-04	Bestätigt	Oppenheimer	Outperform
2013-07-08	Bestätigt	Cantor Fitzgerald	Buy
2013-03-08	Bestätigt	Cantor Fitzgerald	Buy
2013-02-26	Bestätigt	Oppenheimer	Outperform
2013-01-10	Bestätigt	Cantor Fitzgerald	Buy
2012-10-02	Bestätigt	Oppenheimer	Outperform
2012-09-14	Bestätigt	Cantor Fitzgerald	Buy

Alle ansehen

Celldex Therapeutics Inc. Aktie (CLDX) Neueste Nachrichten

Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria

GlobeNewswire Inc.

Down -14.61% in 4 Weeks, Here's Why You Should You Buy the Dip in Celldex (CLDX)

Zacks Investment Research

All You Need to Know About Celldex (CLDX) Rating Upgrade to Buy

Zacks Investment Research

Down -17.39% in 4 Weeks, Here's Why You Should You Buy the Dip in Celldex (CLDX)

Zacks Investment Research

Does Celldex (CLDX) Have the Potential to Rally 71.82% as Wall Street Analysts Expect?

Zacks Investment Research

Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

GlobeNewswire Inc.

Finanzdaten der Celldex Therapeutics Inc.-Aktie (CLDX)

Celldex Therapeutics Inc. (CLDX) Umsatz 2024

Celldex Therapeutics Inc. (CLDX) Nettogewinn 2024

Celldex Therapeutics Inc. (CLDX) Free Cashflow 2024

Celldex Therapeutics Inc. (CLDX) Gewinn je Aktie 2024